Following a year of a huge influx in investment with partnerships and acquisitions specifically directed at developing novel vectors, the 5th Next Generation Gene Therapy Vectors Summit returned as a unique opportunity to connect with a targeted group of vector experts to improve safety and targeting. Sponsors tapped into this dedicated community of vector engineers, preclinical experts, and business development leaders to showcase their partnering capabilities and robust solutions to support their translation to the clinic.

With gene therapy vectors having a pre-disposition to safety and efficacy complexities, these vector developers seeked reliable, time- and cost-effective solutions for vector manufacturing, preclinical models, biodistribution monitoring, and payload design optimization. Could you have helped?

This forum contained such a specific audience comprised of senior decision-makers and commercial leaders at the forefront of vector development, providing the ideal environment to highlight your solution and capabilities as the go-to in this space.